Low-sodium oxybate - Open Access .click

Results 111 to 120 of about 171,176 (147)

Some of the next articles are maybe not open access.

0749 Effectiveness and Safety of Low-Sodium Oxybate by Patient-Reported Long Sleep Need in DUET Study Participants with Idiopathic Hypersomnia

SLEEPJ
Low-sodium oxybate (LXB; Xywav®), the only FDA-approved treatment for idiopathic hypersomnia in adults, was evaluated in the phase 4, open-label DUET study (NCT05875974).
D. Plante +8 more
semanticscholar +1 more source

0762 Improvements in Sleep Inertia with Low-Sodium Oxybate Treatment in Participants with Idiopathic Hypersomnia in the DUET Study

SLEEPJ
People with idiopathic hypersomnia often experience sleep inertia, characterized by profound difficulty waking up with grogginess, disorientation, and cognitive impairment immediately after awakening.
D. Nichols +8 more
semanticscholar +1 more source

1010 Effectiveness and Satisfaction with Low-Sodium Oxybate as Described by Adults Living with Idiopathic Hypersomnia: LYRICAL Survey & Interview Findings

SLEEPJ
Low-sodium oxybate (LXB; Xywav®) is approved in the US for the treatment of idiopathic hypersomnia (IH) in adults. LYRICAL, a longitudinal, mixed methods study, examined the real-world treatment experience of US adults to provide details on the ...
C. Drachenberg +10 more
semanticscholar +1 more source

Corrigendum to “Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study” [Sleep Med. 109 (2023) 65–74 ISSN 1389–9457]